4.7 Review

In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 114, Issue -, Pages 240-255

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2017.04.005

Keywords

Immune tolerance; Nanoparticle; Autoimmune disease; Transplantation; Allergy; Drug delivery; Regulatory T cells

Funding

  1. National Institutes of Health [EB-013198]

Ask authors/readers for more resources

Technologies that induce antigen-specific immune tolerance by mimicking naturally occurring mechanisms have the potential to revolutionize the treatment of many immune-mediated pathologies such as autoimmunity, allograft rejection, and allergy. The immune system intrinsically has central and peripheral tolerance pathways for eliminating or modulating antigen-specific responses, which are being exploited through emerging technologies. Antigen-specific tolerogenic responses have been achieved through the functional reprogramming of antigen presenting cells or lymphocytes. Alternatively, immune privileged sites have been mimicked using biomaterial scaffolds to locally suppress immune responses and promote long-term allograft survival. This review describes natural mechanisms of peripheral tolerance induction and the various technologies being developed to achieve antigen-specific immune tolerance in vivo. As currently approved therapies are non-specific and carry significant associated risks, these therapies offer significant progress towards replacing systemic immune suppression with antigen-specific therapies to curb aberrant immune responses. (C) 2017 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available